MICROBA LIFE SCIENCES LIMITED (MAP)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

MAP

MAP - MICROBA LIFE SCIENCES LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -0.16
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.084

17 Sep
2025

-0.003

OPEN

$0.09

-3.45%

HIGH

$0.09

674,158

LOW

$0.08

TARGET
$0.225 167.9% upside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CSL . CUV . DXB . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MSB . MVP . MYX . NEU . NUZ . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SNT . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
MAP: 1
Title FY24
Actual		 FY25
Actual		 FY26
Forecast		 FY27
Forecast
EPS (cps) xxx - 3.3 - 2.4 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 24/06 - (franking Ex-Di

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx-3.3
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx15.7 M
Book Value Per Share xxxxxxxxxxxxxxx6.3
Net Operating Cash Flow xxxxxxxxxxxxxxx-12.0 M
Net Profit Margin xxxxxxxxxxxxxxx-95.34 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx-40.54 %
Return on Invested Capital xxxxxxxxxxxxxxx-39.53 %
Return on Assets xxxxxxxxxxxxxxx-28.33 %
Return on Equity xxxxxxxxxxxxxxx-40.54 %
Return on Total Capital xxxxxxxxxxxxxxx-62.68 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-12.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx2 M
Long Term Debt xxxxxxxxxxxxxxx2 M
Total Debt xxxxxxxxxxxxxxx3 M
Goodwill - Gross xxxxxxxxxxxxxxx10 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx12 M
Price To Book Value xxxxxxxxxxxxxxx1.35

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx2.9 M
Capex % of Sales xxxxxxxxxxxxxxx18.50 %
Cost of Goods Sold xxxxxxxxxxxxxxx29 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx11 M
Research & Development xxxxxxxxxxxxxxx2 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

2
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

xx/xx/xxxx

1

xxxxxxxxxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

27/08/2025

1

Speculative Buy

$0.29

245.24%

Microba Life Sciences reported FY25 revenue up 30% on the prior year, which met guidance and Morgans' forecast. Net profit after tax losses shrank by -18%, boosted by a one-off reversal of contingent liability related to the Invivo acquisition.

The analyst views the result as messy, with the sale of the research services division and the liability reversal, but the underlying result was broadly in line.

FY26 guidance is for Australia & UK to break even by the end of FY26, with 14% annual growth in revenue. The company also anticipates achieving its first strategic partnerships for MetaXplore in Australia & UK, with groundwork being prepared for the US market.

Speculative Buy rating retained. Target slips to 29c from 31c.

FORECAST
Morgans forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -2.40 cents.
Morgans forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -1.50 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

09/09/2025

1

Buy

$0.19

126.19%

FY25 results for Microba Life Sciences were in line with Canaccord Genuity's expectations.

Revenue grew 30% to $15.7m, driven by MetaXplore and MetaPanel uptake in Australia and the UK, with group margins steady at 47.5%, highlights the broker.

The company reported a -$14.9m loss, reflecting a lower R&D spend, notes the broker.

Management is seeking partners for its Therapeutics division. FY26 guidance is for Australian/EU diagnostics to break even in FY26 on doubled test volumes of around 24,000. 

Pro forma cash stands at circa $23.2m after the recent equity raise and expected R&D Tax Incentive receipts, explains Canaccord.

The broker retains a Buy rating and 19c target price.

FORECAST
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -1.82 cents.
Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -1.63 cents.
Access Extra Coverage Research History >

MAP STOCK CHART

FNArena News on MAP

1
Australian Broker Call *Extra* Edition – Sep 09, 2025

Sep 09 2025 - Daily Market Reports
2
FNArena Corporate Results Monitor – 27-08-2025

Aug 27 2025 - Australia
3
Australian Broker Call *Extra* Edition – Aug 18, 2025 (Extra)

Aug 18 2025 - Daily Market Reports
4
Australian Broker Call *Extra* Edition – Aug 18, 2025

Aug 18 2025 - Daily Market Reports
5
Australian Broker Call *Extra* Edition – Aug 12, 2025

Aug 12 2025 - Daily Market Reports

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Earnings Result Leaves CSL Bloodied

Aug 21 2025 - Australia
2
Renewed Momentum For CSL Shares

Jul 22 2025 - Technicals
3
Treasure Chest: CSL Not A One-Trick Pony

Jul 14 2025 - Treasure Chest
4
The Enigma Surrounding Clinuvel

Jul 03 2025 - Small Caps
5
Rudi’s View: CSL & NextDC

May 08 2025 - Rudi's View
6
Behring Margin Outlook Still Main Game For CSL

Feb 13 2025 - Australia
7
Dr Boreham’s Crucible: Arovella Therapeutics

Aug 29 2024 - Small Caps
8
ResMed’s Margin Upside Excites

Aug 07 2024 - Australia
9
Dr Boreham’s Crucible: Aroa Biosurgery

Jul 29 2024 - Small Caps
10
CSL Shares Breaking Free

Jul 23 2024 - Technicals